Close Menu

GenomeWebinars

Thu
Jun
4
11:00 am2020
Sponsored by
Ovation

COVID-19 Testing, Treatment and Future Outlook

GenomeWebinar

Chief Scientific Officer, Vikor Scientific

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Attendees of this webinar will learn about:

  • The role of PCR and antibody testing in the management of the pandemic;
  • The role of potential treatments for COVID-19 and future vaccines on the management of the pandemic;
  • Actions that need to be taken to mitigate the impact of future pandemics.
Sponsored by

Professor for Molecular Hematology,
Medical Faculty Carl Gustav Carus, Technical University of Dresden

The invention of novel high-throughput technologies, especially next-generation sequencing (NGS), has spurred our understanding of the development of human cancers and opened new avenues for rapid and comprehensive diagnosis. Especially in hematological malignancies, the availability of these novel high-throughput technologies has greatly enhanced our capabilities for the identification of disease, defining lesions and targets for tailored treatment. At the same time, these diagnostic tools have inherent aspects that make them vulnerable to false positives as well as false negatives. Major aspects are balanced coverage, the rate of detection of long insertions and deletions, as well as the sensitivity of the assay. 

Besides these technical aspects, the comprehensive and adequate interpretation of results, especially in the light of more recent discoveries regarding preleukemic, clonal hematopoiesis, such as clonal hematopoiesis with indeterminate potential (CHIP), adds an additional layer of complexity, which requires a substantial level of expertise to avoid over- as well as underinterpretation of results.

Nevertheless, the important information gained by using NGS-based evaluation of patients for the presence of mutations enables much more comprehensive analysis; identification of disease-defining lesions (e.g., mutations in genes like NPM1, CEBPA, SETBP1); and potential targets for treatment (e.g., cKIT, FLT3) and risk stratification (e.g., TP53, RUNX1 or ASXL1).

In this webinar, Dr. Christian Thiede, Professor for Molecular Hematology at the Technical University of Dresden will discuss the pros and cons of these methods, their appropriate and cost-effective use, as well as aspects to keep in mind for data interpretation will be discussed.

For Research Only. Not for use in diagnostics procedures.

Sponsored by
Tue
Jun
9
1:00 pm2020
Sponsored by
Illumina

Enabling Scalable Comprehensive Genomic Profiling from FFPE Samples

GenomeWebinar

Technical Director, Clinical Genomics,
Providence Cancer Center

Staff Product Manager,
Illumina

Senior Scientist,
Illumina

Comprehensive genomic profiling (CGP) is becoming standard of care for cancer and allows pathology labs to consolidate individual biomarkers into a single NGS assay. It enables the assessment of all key biomarkers cited in guidelines and clinical trials using a minimal amount of formalin-fixed, paraffin-embedded (FFPE) tissue while increasing the chance of finding a positive biomarker for every sample. 

Illumina’s TruSight Oncology 500 High-Throughput (TSO500 HT)assay enables labs to perform in-house CGP with scalability on a NovaSeq 6000 platform. 

In this webinar, Brian Piening of Providence Cancer Center will discuss why his team decided to implement in-house CGP and will share analytical performance data from their TSO500_HT runs. He will also provide details of the center’s end-to-end workflow, including the data analysis flow and how they build their final reports.

Attendees of this webinar will learn about: 

  • Providence Cancer Center’s implementation of in-house CGP
  • Illumina’s solution enabling in-house CGP
Sponsored by

Professor, Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology & Head of Cancer Vaccines, Human Longevity Inc.

Medical Oncologist & Assistant Professor of Medicine, UC San Diego Health

 

T-cell receptor (TCR) therapy is a rapidly emerging adaptive cell therapy (ACT) method in the field of cancer immunotherapy. However, the process for developing effective T-cell receptors can be time consuming, particularly with regard to the rigorous functional testing needed prior to scale-up and patient infusion.

In this webinar, Stephen Schoenberger of the La Jolla Institute for Immunology discusses how he is leveraging an automated DNA assembly and cloning platform, the BioXp 3200, to achieve a 10-fold increase in the development of TCRs.

 

Sponsored by
Thu
Jun
11
11:00 am2020
Sponsored by
Stilla

Innovation in Digital PCR: Maximizing Data Output from Precious Samples

GenomeWebinar

Research Assistant,
National Institute of Biology

Director of Molecular Biology R&D,
Stilla Technologies

The commercialization of digital PCR platforms has sparked a revolution in quantitative nucleic acid detection over the past decade. Stilla Technologies’ Naica System, an established easy-to-use digital PCR platform, offers an innovative solution that quantifies in three colors while minimizing time to results.  

This webinar will present the features of the company’s new 6-color Crystal Digital PCR System and highlight a set of applications poised to greatly benefit from the increased multiplexing and high sensitivity of 6-color digital PCR. 

First, Alexandra Bogozalec from the National Institute of Biology in Slovenia will detail how her team has capitalized on the high-plex capacity of 6-color Crystal Digital PCR to simplify the time-consuming GMO quantification workflow and simultaneously quantify a set of genetically modified soybean lines at low target concentrations.  

This webinar will also discuss how the highly sensitive detection capability of 6-color Crystal Digital PCR benefits oncology applications. Allison Mallory of Stilla Technologies will present high-plex mutation detection in non-small cell lung cancer, colorectal and breast cancer samples and will show how 6-color digital PCR enables efficient therapeutic monitoring and early detection of treatment resistance through noninvasive liquid biopsy. 

Sponsored by
Mon
Jun
15
1:00 pm2020
Sponsored by
Thermo Fisher Scientific

Making the Case for Expanded Carrier Screening for Inheritable Genetic Disorders

GenomeWebinar

Vice President, Associate Dean, University of South Florida and Executive Medical Director,
Access to Expanded Carrier Screening Coalition

Advances in DNA sequencing technology have dramatically enhanced our ability to perform more comprehensive genetic risk assessments. Carrier screening protocols for the detection of serious and prevalent inheritable disorders have seen significant evidence-based advances but have experienced slow adoption, limited primarily by education of pregnant women and providers.  

Population demographics and variability in population ethnicity have redefined a couple’s risk for many inheritable autosomal recessive disorders. Advances like next-generation sequencing and sophisticated bioinformatics pipelines have provided insight into carrier frequencies in more diverse populations and identified the gaps that are created by current guidelines.

This webinar is the first in a three part series that will present cases that highlight the benefits of expanded carrier screening research for less well known inheritable conditions.

Join Dr. Brown in this webinar to learn about:

  • The evolution of expanded carrier screening  
  • Current guidelines and their role 
  • Cases highlighting the power of expanded carrier screening  
Sponsored by

Associate Professor,
Department of Integrative Biology & Centre for Biodiversity Genomics, University of Guelph

All living organisms shed DNA into their environment, and these traces of DNA can now be profiled using next-generation sequencing. Thanks to a colossal effort around the world to sequence the molecular markers (e.g. DNA barcodes) of hundreds of thousands of eukaryotic species, we now have databases that allow us to match eDNA to its sources. By using the massive capacity of high-throughput sequencers, we can now survey the presence and dynamics of shifts in biodiversity in different environments and monitor it over time. 

Existing methods for environmental surveys are costly and time consuming, often relying on invasive or destructive sampling methods, and specialist expertise from taxonomists to correctly identify species. Metabarcoding promises to be a complementary alternative that will enable researchers, governments, and industry to gain more comprehensive insights into changes in biodiversity, and make more informed choices around conservation, environmental impact assessment, water quality monitoring, biosecurity, and more. 

This webinar will review recent research and validation experiments demonstrating the power of metabarcoding for a range of potential applications. 

Attendees of this webinar will learn about: 

  • Biodiversity markers and DNA barcoding
  • Metabarcoding and environmental DNA
  • Sample types and sampling regimes
  • Next-generation sequencing approaches for eDNA metabarcoding
  • Bioinformatics for taxonomic assignment and validation
  • Experimental design aspects from sample to data analysis and interpretation
  • Freshwater metabarcoding for water quality assessment
  • Soil metabarcoding for ecological surveys
  • Comprehensive biodiversity assessment in seawater using ultra-deep metabarcoding
Sponsored by

Application Scientist,
Lexogen

Chief Science Officer,
OnRamp Bio 

Epigenetic regulators are constituted by a great diversity of subunits, which are often redundant to varying extents. Novel experimental strategies including genome editing and small molecule-inducible systems allow for systematic dissection of multi-subunit complexes. While these approaches are ideal to assess the transcriptional consequences of combinatorial genetic perturbations to epigenetic pathways, the sequencing costs associated with gene expression analysis by RNA-seq quickly escalate as a function of sample number.

Lexogen QuantSeq facilitates increased multiplexing capacity without ramping up the sequencing costs by focusing on the 3’ ends of mRNAs. Such gene expression profiling approaches require only about 10 percent of sequencing depth compared to standard RNA-seq methods.

In this webinar, Jorge Zepeda from Lexogen will discuss a study conducted at the Institute of Molecular Biotechnology that used small molecule-inducible genetic perturbations in combination with transcriptional profiling by QuantSeq and chromatin immunoprecipitation sequencing (ChIP-seq) analysis to unravel the differential subunit requirements of polycomb repressive complexes 1 (PRC1) and 2 (PRC2), in maintaining robust silencing of lineage-specific genes and self-renewal capacity in mouse embryonic stem cells.

The second speaker, Jean Lozach from OnRamp Bio will demonstrate the capabilities of the OnRamp Bioinformatics discovery platform Rosalind to analyze and integrate multi-omics datasets like the QuantSeq and ChIP-seq used in this study and, will also show a new option for efficient collaboration between researchers.

Sponsored by
Tue
Jun
23
10:00 am2020
Sponsored by
Illumina

Building Global Startups: An Expert Panel on Entrepreneurship in Genomics

GenomeWebinar

Global Head, Illumina Accelerator

Co-founder & CEO, Biome Makers

Co-founder & CEO, Juno Bio

CEO, BioAmp

Co-Founder and Chief Operating Officer, 4baseCare

The decreasing cost of genomic technologies has democratized their use for many biotech and clinical breakthrough applications. Entrepreneurs are playing a key role in advancing these applications by translating scientific breakthroughs and ideas into commercially viable businesses that transcend borders.

Join the Illumina Accelerator and four global genomics startups in the biotech, clinical, and agricultural industries to discuss key trends in entrepreneurship; how to build a genomics startup from ideation to commercialization; how to access capital; and how to navigate and find opportunity in the current challenging climate.

Sponsored by
Wed
Jun
24
11:00 am2020
Sponsored by
NanoString

Implementing Digital Spatial Profiling as a Service: A Core Lab Case Study

GenomeWebinar

Research Scientist, Experimental Pathology; Division of Advanced Research Technologies, New York Langone Medical Center

An increasing number of technologies combine spatial discrimination with molecule identification, as has been done for decades through immunohistochemistry and in situ hybridization. The difference is that now a range of commercially available platforms promises to significantly increase the number of targets that can be identified on a single sample. These platforms also provide higher throughput in terms of the number of samples that can be interrogated, and some offer semi-automation with straightforward sample preparation.

These characteristics promise to make the new spatial profiling technologies attractive candidates for biomedical research facilities, but in order to discriminate between them, it is necessary to share real-world experiences using them in core labs.

This session will share the experience at New York University Langone Health using Nanostring’s GeoMx digital spatial profiling platform as a service for research laboratories. Dr. Valeria Mezzano of NYU Langone will discuss how her team approaches each project, interacts with clinical researchers, and performs the assays as an integrated network of core facilities.

Sponsored by
Tue
Jun
30
1:00 pm2020
Sponsored by
Qiagen

Practices for Clinical Hereditary NGS Variant Interpretation

GenomeWebinar

Founder and CEO,
Blackhawk Genomics

This webinar will discuss the opportunity for clinical laboratories to implement efficient tertiary analysis pipelines and share best practices for selecting and implementing a tertiary analysis pipeline for variant interpretation.

Clinical laboratories are rapidly expanding both the scope and complexity of hereditary services offered utilizing next-generation sequencing. With this expansion come a significant number of challenges including turnaround time, the need for specialized clinical genetic knowledge and overall scalability. Adopting a thoughtful strategy for selection and implementation of appropriate tertiary analysis tools is critical to the success of a clinical NGS program.

In this educational webinar, Dr. Tootie Tatum of Blackhawk Genomics will discuss the following:

  • Market trends and opportunities for clinical laboratories performing hereditary NGS
  • Current challenges in NGS interpretation and ways to overcome them
  • Propose strategies to introduce NGS into the laboratory
  • Aligning the capabilities of variant interpretation solutions with laboratory resources
  • The importance of depth, breadth and completeness of quality variant interpretation content
Sponsored by
Thu
Jul
9
1:00 pm2020
Sponsored by
Illumina

Our Magic DRAGEN: A Sequencing Lab Case Study on Accelerated Bioinformatics

GenomeWebinar

Executive Director and Founder, Texas A&M AgriLife Genomics and Bioinformatics Service

Global Product Marketing Manager, Software, Illumina

In this webinar, Dr. Charlie Johnson, founder of the Texas A&M AgriLife Genomics and Bioinformatics Service, will share how his team is utilizing Illumina’s DRAGEN informatics platform in its high-throughput agrigenomics research program. 

Increases in sequencing power, laboratory automation, and bioinformatics have revolutionized agriculture genomics, but until the rise of the DRAGEN system, computing was the biggest roadblock for Dr. Johnson’s team. He will discuss how the platform has enabled his lab to reduce post-run data processing time from days to hours and in some cases minutes.

Dr. Johnson will also share how his team has expanded use of the DRAGEN system across the whole analysis pipeline, describe areas where the power of the platform’s hardware acceleration provides the best performance, and outline work being done to further improve efficiency.

Illumina’s Stephanie Black will review the DRAGEN technology, discuss key application areas, summarize recent advancements, and walk through the growing DRAGEN access points, both on-premises and in the cloud.

Sponsored by
Wed
Jul
15
11:00 am2020
Sponsored by
LGC SeraCare Life Sciences

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

GenomeWebinar

Chief Scientific Officer, Foundation Medicine

Global Head of Medical Affairs,
Clinical NGS and Oncology Division, Thermo Fisher Scientific

VP Translational Science, Oncology, AstraZeneca

President & Chief Technology Officer,  Genosity

Vice President, Assay Development, Illumina

Chief Scientific Officer, LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer. However, only a minority of patients with terminal cancer have durable response with approved immuno-oncology treatments.

This webinar will feature a panel of experts in the field who will provide key insights into the current advances in cancer diagnostics and immunotherapy, as well as challenges facing the discipline.

The panelists bring a wealth of expertise and differing viewpoints in clinical laboratory practice, cancer research, translational sciences, and immuno-oncology diagnostics and therapeutics at the molecular and cellular levels important to the care and management of cancer patients and treatment outcomes. Each speaker will have an opportunity to share their perspectives on this topic, which will be moderated by Dr. Russell Garlick, Chief Scientific Officer at LGC SeraCare. The presentation will be followed by a live Q&A to allow attendees to address the experts directly.

Sponsored by
Wed
Jul
22
12:00 pm2020
Sponsored by
Thermo Fisher Scientific

Advances in Genetic Testing for IVF Research: PGT-A, PGT-M, and Carrier Screening

GenomeWebinar

Scientific and Lab Director,
Bioarray & Journey Genomics

This webinar is the second in a three part series that will provide an overview of how cutting-edge genomic technologies based on next-generation sequencing (NGS) are streamlining in vitro fertilization research workflows*. 

Luis A. Alcaraz, cofounder of Bioarray and Journey Genomics, accredited diagnostic and research labs based in Alicante, Spain, will review how his teams use advanced genomic techniques for carrier screening research as well as for preimplantation genetic testing (PGT) in embryos for both aneuploidies (PGT-A) and monogenic disorders (PGT-M).

These technologies deliver greater efficiency to Bioarray and Journey Genomics, allowing faster delivery of meaningful results and reports for geneticists and researchers, which in turn is increasing their customer outcomes. 

In this webinar you will learn:

  • How to study PGT-A and PGT-M with NGS  
  • How expanded carrier screening with NGS screens for 420 genes in a single assay
  • How new molecular techniques are improving workflows at Bioarray and Journey Genomics

*For research use only. Not for use in diagnostic procedures.

Sponsored by

Kindai Nara University Hospital,
Department of Medical Oncology

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Takayuki Takahama of Kindai Nara University Hospital will share details of the study, which enrolled 276 patients with advanced or recurrent NSCLC with known TKI-sensitizing mutations of EGFR, had documented disease progression after treatment with at least 1 first- or second-generation EGFR TKI, and were positive for the T790M mutation in plasma.

Dr. Takahama will discuss the results, which demonstrate the utility of liquid biopsy for the detection of T790M with the cobas EGFR Mutation Test v2. Plasma genotyping with this assay is informative for treatment selection in clinical practice when tumor sampling is not feasible. 

Sponsored by
Thu
Sep
17
1:00 pm2020
Sponsored by
Thermo Fisher Scientific

Clinical Diagnosis of Developmental Disorders with Chromosomal Microarrays

GenomeWebinar

Senior Director, Cytogenetics Laboratory,
Greenwood Genetic Center

The prevalence of developmental disability among US children aged 3 to 17 years increased between 2009 and 2017, with as many as 1 in 6 children in the US reported to have a developmental disability diagnosis. Developmental delay/intellectual disability (DD/ID) is frequently accompanied with one or more congenital anomalies or dysmorphic features. 

Chromosomal microarrays (CMA) are an established technology that has demonstrated great sensitivity and specificity for detecting genome-wide copy number variants (CNVs) and now represents a robust technical platform for both medical genetics research and clinical services. The American Academy of Neurology, the American College of Medical Genetics, and the International Collaboration for Clinical Genomics recommend CMAs as the first-line test to aid in the diagnostic evaluation of intellectual disability.

CMA is replacing traditional karyotype and FISH as the first-line genetic test due to its greater sensitivity, higher resolution, genome-wide capability, and greater diagnostic yield. The CytoScan Dx Assay is the first FDA-cleared chromosomal microarray test to aid in the identification of the underlying genetic cause of developmental delay, intellectual disability, congenital anomalies, or dysmorphic features in children.

Join Barb Dupont from Greenwood Genetic Center to: 

  • Learn about the importance of CMA postnatal assessments for developmental delay, intellectual disability, congenital anomalies, or dysmorphic features
  • Discover the advantages of using a higher-resolution CMA solution when compared to conventional techniques such as karyotyping and FISH
  • Understand how CMA results from CytoScan Dx Assay can be used in conjunction with other clinical and diagnostic findings by healthcare professionals
Sponsored by

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.